These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 5317012)

  • 41. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
    Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
    Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Controlled trial of inactivated influenza vaccine containing the a-Hong Kong strain during an outbreak of influenza due to the a-England-42-72 strain.
    Hoskins TW; Davies JR; Allchin A; Miller CL; Pollock TM
    Lancet; 1973 Jul; 2(7821):116-20. PubMed ID: 4124042
    [No Abstract]   [Full Text] [Related]  

  • 43. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong.
    Cowling BJ; Ng S; Ma ES; Cheng CK; Wai W; Fang VJ; Chan KH; Ip DK; Chiu SS; Peiris JS; Leung GM
    Clin Infect Dis; 2010 Dec; 51(12):1370-9. PubMed ID: 21067351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
    Monto AS; Petrie JG; Cross RT; Johnson E; Liu M; Zhong W; Levine M; Katz JM; Ohmit SE
    J Infect Dis; 2015 Oct; 212(8):1191-9. PubMed ID: 25858957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.
    Nicholson KG; Colegate AE; Podda A; Stephenson I; Wood J; Ypma E; Zambon MC
    Lancet; 2001 Jun; 357(9272):1937-43. PubMed ID: 11425416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trials of aqueous killed influenza vaccine in Canada, 1968-69.
    Williams MC; Davignon L; McDonald JC; Pavilanis PV; Boudreault A; Clayton AJ
    Bull World Health Organ; 1973; 49(4):333-40. PubMed ID: 4605401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potentiation of the antibody response to inactivated A2-Hong Kong vaccines by previous heterotypic influenza virus infection.
    Potter CW; Jennings R; Marine WM; McLaren C
    Microbios; 1973; 8(30):101-10. PubMed ID: 4801251
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn.
    Blanchard-Rohner G; Meier S; Bel M; Combescure C; Othenin-Girard V; Swali RA; Martinez de Tejada B; Siegrist CA
    Pediatr Infect Dis J; 2013 Dec; 32(12):1374-80. PubMed ID: 24569309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antibody response to anti-influenza vaccination with A2-Hong Kong-68 and B-Roma-1-67 bivalent vaccine].
    Dal Fabbro G; Valletta G; Frugoni G; Ricciardi-Tenore N
    Minerva Med; 1972; 63(38):2167-71. PubMed ID: 4664783
    [No Abstract]   [Full Text] [Related]  

  • 55. Influenza immunization: clinical studies with ether-split subunit vaccines.
    Brandon FB; Cox F; Quinn E; Timm EA; McLean IW
    Bull World Health Organ; 1969; 41(3):629-37. PubMed ID: 5309487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of subcutaneous, nasal, and combined influenza vaccination. I. Antigenicity.
    Gwaltney JM; Edmondson WP; Rothenberg R; White PW
    Am J Epidemiol; 1971 Jun; 93(6):472-9. PubMed ID: 5562719
    [No Abstract]   [Full Text] [Related]  

  • 57. A comparison of subcutaneous, nasal, and combined influenza vaccination. II. Protection against natural challenge.
    Edmondson WP; Rothenberg R; White PW; Gwaltney JM
    Am J Epidemiol; 1971 Jun; 93(6):480-6. PubMed ID: 5562720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to influenza vaccine by renal transplant patients.
    Carroll RN; Marsh SD; O'Donoghue EP; Breeze DC; Shackman R
    Br Med J; 1974 Jun; 2(5921):701-3. PubMed ID: 4605057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A clinical and serologic comparison of standard and purified bivalent inactivated influenza vaccines.
    Finklea JF; Sandifer SH; Peck FB; Manos JP
    J Infect Dis; 1969 Dec; 120(6):708-12. PubMed ID: 4911903
    [No Abstract]   [Full Text] [Related]  

  • 60. Antigenicity of influenza vaccine from bovine cell cultures.
    Leiderman E; Mogabgab WJ
    Appl Microbiol; 1969 Oct; 18(4):596-600. PubMed ID: 4905036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.